Evidence map›Paper›PMID 41550465›Full record

ArticleMedComm2026

Low Dose of IL-2 Application for Graft-Versus-Host Disease Prophylaxis Following Haploidentical Stem Cell Transplantation.

Zheng-Li Xu, Meng Lv, Xing-Xing Yu, Yi-Yang Ding, Ting-Ting Han, Hai-Xia Fu, Yuan-Yuan Zhang, Xiao-Dong Mo, Yu-Qian Sun, Lan-Ping Xu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zheng-Li XuPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy For Hematologic Malignancies Beijing China.
Meng LvPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy For Hematologic Malignancies Beijing China.
Xing-Xing YuPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy For Hematologic Malignancies Beijing China.
Yi-Yang DingPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy For Hematologic Malignancies Beijing China.
Ting-Ting HanPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy For Hematologic Malignancies Beijing China.
Hai-Xia FuPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy For Hematologic Malignancies Beijing China.
Yuan-Yuan ZhangPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy For Hematologic Malignancies Beijing China.
Xiao-Dong MoPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy For Hematologic Malignancies Beijing China.
Yu-Qian SunPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy For Hematologic Malignancies Beijing China.
Lan-Ping XuPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy For Hematologic Malignancies Beijing China.
Xiao-Hui ZhangPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy For Hematologic Malignancies Beijing China.
Yu WangPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy For Hematologic Malignancies Beijing China.
Xiao-Jun HuangPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy For Hematologic Malignancies Beijing China.ORCID https://orcid.org/0000-0002-2145-6643
Xiang-Yu ZhaoPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy For Hematologic Malignancies Beijing China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graft-versus-host disease (GVHD) are still key obstacles of haploidentical transplantation. Interleukin-2 (IL-2) could promote natural killer (NK) cells and T-regulatory cells (Tregs) cells expansion in vitro and in vivo. We explored whether low-dose IL-2 administration at an early stage could promote NK cells and Tregs reconstitution and reduce GVHD after haplo-HSCT. This cohort trial included 10 recipients of accepting IL-2 treatment and case-pairing 30 recipients without IL-2 treatment post haplo-HSCT. In contrast to the control group, the 5-year incidence of chronic GVHD (cGVHD) was lower (

Indexed as

graft‐versus‐host diseasehaploidentical transplantationinterleukin‐2natural killer cellsT‐regulatory cells

Identifiers

PMID41550465
PMCPMC12805531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.